Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.

Horizontal portrait of Dani Prieto-Alhambra

Dani leads Pharmaco- and Device Epidemiology research at NDORMS and is currently investigating the use, safety, and effectiveness of COVID-19 therapies and vaccines.

On being elected to the Board, Dani said "Being elected as the Academic representative for Europe/Africa is a great opportunity and a responsibility. Setting the standards for research into the safety of medicines and vaccines is more important now than ever. I will be delighted to represent the values of academia in the BoD to make sure ISPE continues to be a welcoming, inclusive society that strives to improve the quality and methodological standards of pharmacoepidemiology globally."

ISPE is a large international scientific society that sets the basis for methodological and clinical research into the use and the effects of medicines in routine practice settings. The ISPE Board of Directors decides on all aspects related to the management and planning of ISPE's activities.

Similar stories

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.

New Botnar Research Institute Director starts today

Professor Jonathan Rees begins his new role as Director of the Botnar Research Institute today, taking over from Professor Andrew Carr.